Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice

Molecular Neurodegeneration

Philip C Wong³  Juan C Troncoso²  Alena V Savonenko²  Joanne S Allard¹  Dexter L Lee¹  Kebreten F Manaye¹  Katherine D LaClair³ 

[1] Department of Physiology and Biophysics, Howard University College of Medicine, 520 W Street, NW Suite 2305, Washington, DC 20059, USA;Department of Neurology, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross 558, Baltimore, MD 21205, USA;Program in Cellular and Molecular Medicine, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross 558, Baltimore, MD 21205, USA

关键词: Cognition;    APOE;    RXR agonist;    Mouse model;    Alzheimer’s disease;    Bexarotene;   

Others  :  862321
DOI  :  10.1186/1750-1326-8-18

 received in 2013-03-28, accepted in 2013-06-06,  发布年份 2013

【 授权许可】

   
2013 LaClair et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR: Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004, 13(2):159-70.
• [2]Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, Yang J, Miao F, Ross CJ, van Eck M, Hayden MR, van Nostrand W, St George-Hyslop P, Westaway D, Wellington CL: Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant a beta in plasma. Neurobiol. Dis. 2006, 24(1):114-27.
• [3]Wong PC, Savonenko A, Li T, Price DL, In Basic neurochemistry: Neurobiology of Alzheimer’s disease. Oxford: Elsevier Inc: Eighth Edition. Edited by Brady S, Albers P; 2012:815-828.
• [4]Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE: ApoE promotes the proteolytic degradation of abeta. Neuron 2008, 58(5):681-93.
• [5]Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, Mitani A, Joyner D, Thyssen DH, Bacskai BJ, Frosch MP, Spires-Jones TL, Finn MB, Holtzman DM, Hyman BT: Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J Neurosci 2012, 32(43):15181-92.
• [6]Roses AD, Saunders AM: APOE is a major susceptibility gene for Alzheimer's disease. Curr Opin Biotechnol 1994, 5(6):663-667.
• [7]Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM: Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med 2011, 3(89):89ra57.
• [8]Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, LaDu MJ, Rostagno A, Frangione B, Ghiso J: Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J. 2000, 348:359-65.
• [9]Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL: Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem. 2004, 279:41197-41207.
• [10]Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM: ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem. 2004, 279:40987-40993.
• [11]Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV: Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007, 27:909-918.
• [12]Morikawa M, Fryer JD, Sullivan PM, Christopher EA, Wahrle SE, DeMattos RB, O'Dell MA, Fagan AM, Lashuel HA, Walz T, Asai K, Holtzman DM: Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta. Neurobiol Dis. 2005, 19:66-76.
• [13]Cramer P, Cirroto J, Wesson D, Lee CY, Karlo J, Zinn A, Casali B, Restivo J, Goebel W, James M, Brunden K, Wilson D, Landreth GE: ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 2012, 23(335):1503-1506.
• [14]Fitz NF, Cronican AA, Lefterov I, Koldamova R: Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science Tech. Comments 2013, 340:924-c.
• [15]Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, Felsenstein KM: Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science Tech. Comments 2013, 340:924-d.
• [16]Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, Gijsen H, Moechars D, Mercken M, Kemp J, D’Hooge R, De Strooper B: Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science Tech. Comments 2013, 340:924-e.
• [17]Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS: Science Tech. Comments. 2013, 340:924-f.
• [18]Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC: Augmented senile plaque load in aged female β-amyloid precursor protein – transgenic mice. Am. J. Pathol. 2001, 158(3):1173-1177.
• [19]Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM: Overexpression of low density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular a-beta clearance. Neuron 2009, 64:632-644.
• [20]Damoiseaux JS, Seeley WW, Zhou J, Shirer WR, Coppola G, Karydas A, Rosen HJ, Miller BL, Kramer JH, Greicius MD: Gender modulates the APOE ϵ4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci 2012, 32(24):8254-62.
• [21]Zelcer N, Khanlou N, Clare R, Jiang W, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P: Attenuation of neuroinflammation and Alzheimer’s disease pathology by liver x receptors. Proc Natl Acad Sci USA 2007, 104(25):10601-6.
• [22]Ohsawa K, Imai Y, Kanazawa H, Sasaki Y, Kohsaka S: Involvement of Iba1 in membrane ruffling and phagocytosis of macrophages/microglia. J. Cell Sci. 2000, 113:3073-3084.
• [23]Kettenmann H, Hanisch U-K, Noda M, Verkhratsky A: Physiology of microglia. Physiol. Rev. 2011, 91(2):461-553.
• [24]McHugh TJ, Tonegawa S: CA3 NMDA receptors are required for the rapid formation of a salient contextual representation. Hippocampus 2009, 19:1153-1158.